Limitations, agreements, and source contact

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma · Source last updated 2026-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

jacobp_laubach@dfci.harvard.edu

organization

Dana Farber Cancer Institute

phone

617-632-4218

title

Dr. Jacob P. Laubach

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice